Gilead Sciences Inc (GILD)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 6,912,000 | 5,840,000 | 8,302,000 | 1,703,000 | 5,182,000 |
| Revenue | US$ in thousands | 26,229,000 | 26,413,000 | 26,325,000 | 24,689,000 | 22,449,000 |
| Pretax margin | 26.35% | 22.11% | 31.54% | 6.90% | 23.08% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $6,912,000K ÷ $26,229,000K
= 26.35%
The pretax margin of Gilead Sciences, Inc. has fluctuated over the past five years, as indicated by the data provided. In 2023, the pretax margin increased to 25.30%, reflecting an improvement in the company's ability to generate profits before accounting for taxes on its revenues. This represents a positive trend from the prior year, where the pretax margin stood at 21.31%, indicating a stronger profitability performance.
Comparing 2023 to 2021, there was a notable decrease in the pretax margin from 30.32% to 25.30%. This decline suggests a potential reduction in profitability efficiency and cost management during this period. However, it is worth noting that the 2021 pretax margin was significantly higher than the margins in 2020 and 2019, which were 6.76% and 22.99%, respectively.
Overall, Gilead Sciences, Inc. has demonstrated varying levels of pretax profitability in recent years, with the most recent data indicating a positive improvement compared to the prior year. Investors and stakeholders may want to further investigate the factors driving these fluctuations in the company's pretax margin to gain a deeper understanding of its financial performance and stability.
Peer comparison
Dec 31, 2023